Our Services
Medical Information
Helpful Resources
Published on: 7/2/2026
GLP-1 receptor agonists can help PCOS patients achieve 5–15% weight loss within 3–6 months, improving insulin resistance, lowering androgen levels, and restoring regular menstrual cycles and ovulation. These benefits may also boost fertility, improve egg quality, and reduce long-term metabolic and cardiovascular risks.
Because dosing, side effects, and monitoring vary by individual, the right treatment path depends on your unique symptoms and health profile. Since PCOS symptoms overlap with many other conditions—like thyroid disorders, insulin resistance, or hormonal imbalances—the smartest first step is getting clarity on what you're actually experiencing. Take a free, instant, online symptom check to better understand your symptoms and confidently navigate your next steps in care.
Reviewed for medical accuracy: 07/02/2026
Polycystic Ovarian Syndrome (PCOS) affects up to 10% of people with ovaries worldwide. It often brings irregular periods, acne, excess hair growth and, importantly, weight gain that can be hard to reverse. Recent clinical interest has turned toward glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a promising avenue for improving weight and hormonal health in PCOS. Below, we explore how GLP-1 therapy works, review the evidence for its benefits, and offer practical guidance.
Weight gain and difficulty losing weight are core challenges in PCOS. Excess body fat—especially around the abdomen—can:
Even a 5–10% reduction in body weight can lead to:
That's where GLP-1s for PCOS weight loss have attracted attention.
GLP-1 receptor agonists are medications that mimic a naturally occurring gut hormone, GLP-1, which is released after eating. Key actions include:
Originally approved for type 2 diabetes, several GLP-1 RAs have since gained approval for chronic weight management. Commonly prescribed agents include:
Multiple small trials and observational studies have evaluated GLP-1 RAs in people with PCOS. While research is ongoing, key findings include:
Weight loss is the cornerstone of managing PCOS symptoms. GLP-1 RAs help by:
Practical considerations:
GLP-1 RAs are generally well tolerated. Common side effects—usually mild to moderate and temporary—include:
Serious but rare risks:
Before starting therapy, your healthcare provider will:
Comprehensive Assessment
Symptom Tracking
Lifestyle Foundation
Medication Initiation
Ongoing Monitoring
While weight loss is a primary driver of symptom improvement, GLP-1 RAs may have direct hormonal effects:
These benefits may translate into:
GLP-1 RAs offer a promising strategy for many people with PCOS, particularly those who:
However, therapy should always be personalized. If you're experiencing concerning symptoms, consider taking a free AI-powered assessment to better understand your Polycystic Ovarian Syndrome (PCOS) symptom profile and discuss the results with your healthcare provider.
PCOS can impact multiple systems in the body. Always seek medical advice if you experience:
Your healthcare provider can help you weigh the benefits and risks of GLP-1 therapy, customize your treatment plan, and monitor progress closely.
Bottom Line
GLP-1 receptor agonists represent an exciting advance in the treatment of PCOS, especially for those struggling with weight and metabolic issues. By targeting appetite, insulin sensitivity and hormonal balance, these medications can unlock improvements in weight, menstrual health and fertility. Speak to your doctor to see if adding a GLP-1 RA to your PCOS management plan could be right for you.
(References)
* Jensterle M, Drinovec B, Považan P, et al. Effects of liraglutide on metabolic and hormonal parameters in obese women with polycystic ovary syndrome: a randomized, placebo-controlled trial. Endocr Pract. 2017 Jul;23(7):826-836.
* El Kindy A, Fendri S, Bouzidi R, et al. Liraglutide effects on hormonal and metabolic profiles in obese women with polycystic ovary syndrome. Clin Exp Reprod Med. 2021 Dec;48(4):307-314.
* Zhu Y, He B. Efficacy of glucagon-like peptide-1 receptor agonists in the treatment of polycystic ovary syndrome: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022 Sep 27;13:969062.
* Feng H, Li Y, Chen X, et al. Effects of liraglutide on clinical and biochemical parameters in overweight and obese women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. J Obstet Gynaecol Res. 2023 Mar;49(3):727-738.
* Jensterle M, Pipal M, Ožek D, et al. GLP-1 Receptor Agonists for Obesity Management in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Int J Mol Sci. 2023 Apr 19;24(8):7470.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.